Phuong N. Huynh

Array ( [id] => 6195471 [patent_doc_number] => 20110027225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-03 [patent_title] => 'MN/CA IX and EGFR Pathway Inhibition' [patent_app_type] => utility [patent_app_number] => 12/900282 [patent_app_country] => US [patent_app_date] => 2010-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18461 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0027/20110027225.pdf [firstpage_image] =>[orig_patent_app_number] => 12900282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6149333 [patent_doc_number] => 20110020928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'IMMUNOVECTORS WHICH CAN BE USED FOR THE INTRACELLULAR AND INTRANUCLEAR TRANSPORT' [patent_app_type] => utility [patent_app_number] => 12/899170 [patent_app_country] => US [patent_app_date] => 2010-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7770 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020928.pdf [firstpage_image] =>[orig_patent_app_number] => 12899170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6145227 [patent_doc_number] => 20110130547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'Reagents For The Detection Of Protein Phosphorylation In EGFR Signaling Pathways' [patent_app_type] => utility [patent_app_number] => 12/897363 [patent_app_country] => US [patent_app_date] => 2010-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20472 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0130/20110130547.pdf [firstpage_image] =>[orig_patent_app_number] => 12897363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6148741 [patent_doc_number] => 20110020336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'Combination Of A Beta-Glucan And An EGF Receptor Antagonist For The Treatment Of Cancer And Infection' [patent_app_type] => utility [patent_app_number] => 12/896692 [patent_app_country] => US [patent_app_date] => 2010-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21383 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020336.pdf [firstpage_image] =>[orig_patent_app_number] => 12896692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5943531 [patent_doc_number] => 20110104151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-05 [patent_title] => 'MICROPARTICLE COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION' [patent_app_type] => utility [patent_app_number] => 12/896278 [patent_app_country] => US [patent_app_date] => 2010-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 25775 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0104/20110104151.pdf [firstpage_image] =>[orig_patent_app_number] => 12896278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8453971 [patent_doc_number] => 20120264916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-18 [patent_title] => 'Methods of Preventing and Removing Trisulfide Bonds' [patent_app_type] => utility [patent_app_number] => 13/499858 [patent_app_country] => US [patent_app_date] => 2010-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 26505 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13499858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8591451 [patent_doc_number] => 08349326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-01-08 [patent_title] => 'Methods and systems for multi-antibody therapies' [patent_app_type] => utility [patent_app_number] => 12/889511 [patent_app_country] => US [patent_app_date] => 2010-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 14407 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12889511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5984509 [patent_doc_number] => 20110097321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-28 [patent_title] => 'COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 12/890101 [patent_app_country] => US [patent_app_date] => 2010-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17420 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0097/20110097321.pdf [firstpage_image] =>[orig_patent_app_number] => 12890101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9957376 [patent_doc_number] => 09005574 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-14 [patent_title] => 'Proteins with high immunoreactivity and method for their production' [patent_app_type] => utility [patent_app_number] => 12/883620 [patent_app_country] => US [patent_app_date] => 2010-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 9121 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12883620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8870367 [patent_doc_number] => 08465743 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-18 [patent_title] => 'Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer' [patent_app_type] => utility [patent_app_number] => 13/499349 [patent_app_country] => US [patent_app_date] => 2010-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 26740 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13499349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8876015 [patent_doc_number] => 08470980 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-25 [patent_title] => 'Extracellular targeted drug conjugates' [patent_app_type] => utility [patent_app_number] => 12/878775 [patent_app_country] => US [patent_app_date] => 2010-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 11 [patent_no_of_words] => 49786 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12878775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6083671 [patent_doc_number] => 20110144035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'Methods and Compositions for Treating Conditions of the Eye' [patent_app_type] => utility [patent_app_number] => 12/877662 [patent_app_country] => US [patent_app_date] => 2010-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13521 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0144/20110144035.pdf [firstpage_image] =>[orig_patent_app_number] => 12877662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9153809 [patent_doc_number] => 08586714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-11-19 [patent_title] => 'Dual variable domain immunoglobulins and uses thereof' [patent_app_type] => utility [patent_app_number] => 12/873926 [patent_app_country] => US [patent_app_date] => 2010-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 94027 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12873926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6351378 [patent_doc_number] => 20100331279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-30 [patent_title] => 'Inhibition of Antigen Presentation with Poorly Catabolized Polymers' [patent_app_type] => utility [patent_app_number] => 12/872620 [patent_app_country] => US [patent_app_date] => 2010-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5248 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0331/20100331279.pdf [firstpage_image] =>[orig_patent_app_number] => 12872620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9073905 [patent_doc_number] => 08551480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-08 [patent_title] => 'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity' [patent_app_type] => utility [patent_app_number] => 12/871345 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 32982 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12871345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6148678 [patent_doc_number] => 20110020273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof' [patent_app_type] => utility [patent_app_number] => 12/869823 [patent_app_country] => US [patent_app_date] => 2010-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 35535 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020273.pdf [firstpage_image] =>[orig_patent_app_number] => 12869823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9254437 [patent_doc_number] => 08617849 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-31 [patent_title] => 'Velocity factor' [patent_app_type] => utility [patent_app_number] => 13/392217 [patent_app_country] => US [patent_app_date] => 2010-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 8660 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13392217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6073019 [patent_doc_number] => 20110047103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-24 [patent_title] => 'ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 12/854711 [patent_app_country] => US [patent_app_date] => 2010-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 25179 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0047/20110047103.pdf [firstpage_image] =>[orig_patent_app_number] => 12854711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8323451 [patent_doc_number] => 20120195858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-02 [patent_title] => 'RESPONSIVENESS TO ANGIOGENESIS INHIBITORS' [patent_app_type] => utility [patent_app_number] => 13/388840 [patent_app_country] => US [patent_app_date] => 2010-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 25657 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13388840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6178524 [patent_doc_number] => 20110178279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 12/849786 [patent_app_country] => US [patent_app_date] => 2010-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 10279 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20110178279.pdf [firstpage_image] =>[orig_patent_app_number] => 12849786 [rel_patent_id] =>[rel_patent_doc_number] =>)